AxoGen ( (AXGN) ) just unveiled an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Axogen, Inc., a leader in peripheral nerve repair solutions, reported a notable 17.9% revenue increase for Q3 2024 at $48.6 million, alongside a decrease in net loss to $1.9 million from $4.1 million in the previous year. The company’s strategic advancements include FDA acceptance of its Biologics License Application for Avance Nerve Graft and promising engagement at industry events. Axogen aims to hit the high end of its revenue and gross margin guidance while maintaining its commitment to improving nerve repair standards globally.
Find detailed analytics on AXGN stock on TipRanks’ Stock Analysis page.
